secwatch.observer — SEC 8-K summary
======================================

Issuer:     XOMA Royalty Corp (XOMA)
CIK:        0000791908
Form:       8-K
Filed at:   2023-08-25T23:59:59+00:00
Accession:  0001193125-23-221604
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Novartis discontinues development of XOMA-licensed NIS793 anti-TGFß antibody
----------------------------------------------------------------------------

- On Aug 25, 2023, Novartis notified XOMA it will stop development of NIS793 (anti-TGFß monoclonal antibody).
- Novartis will cease enrolling patients in remaining active TGFß clinical studies and collect final data.
- XOMA licensed NIS793 to Novartis in September 2015; no milestones or royalties mentioned in the filing.
- NIS793 is investigational; efficacy/safety not established and no guarantee of commercial availability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/791908/000119312523221604/0001193125-23-221604-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/791908/000119312523221604/d528666d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-221604

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer